Stem Cell Therapy for Perianal Crohn’s Disease

Knyazev, Oleg; Fadeeva, N A; Каграманова, А В; Belyakov, N I; Орлова, Н. В.; Lishchinskaya, A; Konoplyannikov, Anatoly; Парфенов, А И

doi:10.26442/terarkh201890360-66

Cited by 14 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They demonstrated that combined cell and anti-cytokine therapy with CZP of CD with perianal lesions promotes more frequent and prolonged closure of simple fistulas, compared with BSCs monotherapy and CZP monotherapy. Knyazev et al [ 67 ] performed a clinical trial to compare the effectiveness of combination therapy with BSCs, anticytokine therapy with infliximab (IFX), and antibiotic/immunosuppressive therapy in CD fistulas. They demonstrated that combined cellular and anticytokine therapy of CD with perianal lesions significantly contributes to the more frequent and prolonged closure of simple fistulas, as compared to antibiotics/immunosuppressors, and to a decrease in the frequency of recurrence of the disease.…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stem cells transplantation for perianal fistulas: a systematic review and meta-analysis of clinical trials

Wang

Jiang²,

Zhang

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

Background Perianal fistulas, characterised as granulomatous inflammation of fistulas around the anal canal, are associated with significant morbidity resulting in a negative impact on quality of life and a tremendous burden to the healthcare system. Treatment of anal fistulas usually consists of anal surgery; however, results of closure rates are not satisfactory especially with complex perianal fistulas, after which many patients may suffer from anal incontinence. Recently, the administration of mesenchymal stem cells (MSCs) has shown promising efficacy. Herein, we aim to explore whether MSCs are effective for complex perianal fistulas and if they have either short-term, medium-term, long-term or over-long-term efficacy. Additionally, we want to elucidate whether factors such as drug dosage, MSC source, cell type, and disease aetiology influence treatment efficacy. Main body of the abstract We searched four online databases and analysed data based on information within the clinical trials registry. The outcomes of eligible trials were analysed with Review Manager 5.4.1. Relative risk and related 95% confidence interval were calculated to compare the effect between the MSCs and control groups. In addition, the Cochrane risk of bias tool was applied to evaluate the bias risk of eligible studies. Meta-analyses showed that therapy with MSCs was superior to conventional treatment for complex perianal fistulas in short-, long- and over-long-term follow-up phases. However, there was no statistical difference in treatment efficacy in the medium term between the two methods. Subgroup meta-analyses showed factors including cell type, cell source and cell dosage were superior compared to the control, but there was no significant difference between different experimental groups of those factors. Besides, local MSCs therapy has shown more promising results for fistulas as a result of Crohn’s Disease (CD). Although we tend to maintain that MSCs therapy is effective for cryptoglandular fistulas equally, more studies are needed to confirm this conclusion in the future. Short conclusion MSCs Transplantation could be a new therapeutic method for complex perianal fistulas of both cryptoglandular and CD origin showing high efficacy in the short-term to over-long-term phases, as well as high efficacy in sustained healing. The difference in cell types, cell sources and cell dosages did not influence MSCs’ efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Mesenchymal stem cells transplantation for perianal fistulas: a systematic review and meta-analysis of clinical trials

Wang

Jiang²,

Zhang

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“… At 1-year, healing of 58.3% (7/12) in group 1, 60% (6/10) in group 2, and 14.3% (2/14) in group 3. [ 189 ] Herreros M. D. 2019, Spain I/II CD (18 with perianal CD) 45 Auto-ASCs allo-ASCs Local / IV Nothing >6 month 55.5% of CD patients achieved healing (absence of suppuration). CD patients receiving SVF, auto-ASCs and allo-ASCs were cured by 40%, 66.6% and 55.5% respectively.…”

Section: Therapeutic Effects Of Scs In Ibdmentioning

confidence: 99%

Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges

Tian¹,

Zhang²,

Yang³

et al. 2023

JIR

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a group of chronic inflammatory diseases of the gastrointestinal tract. Repeated inflammation can lead to complications, such as intestinal fistula, obstruction, perforation, and bleeding. Unfortunately, achieving durable remission and mucosal healing (MH) with current treatments is difficult. Stem cells (SCs) have the potential to modulate immunity, suppress inflammation, and have anti-apoptotic and pro-angiogenic effects, making them an ideal therapeutic strategy to target chronic inflammation and intestinal damage in IBD. In recent years, hematopoietic stem cells (HSCs) and adult mesenchymal stem cells (MSCs) have shown efficacy in treating IBD. In addition, numerous clinical trials have evaluated the efficiency of MSCs in treating the disease. This review summarizes the current research progress on the safety and efficacy of SC-based therapy for IBD in both preclinical models and clinical trials. We discuss potential mechanisms of SC therapy, including tissue repair, paracrine effects, and the promotion of angiogenesis, immune regulation, and anti-inflammatory effects. We also summarize current SC engineering strategies aimed at enhancing the immunosuppressive and regenerative capabilities of SCs for treating intestinal diseases. Additionally, we highlight current limitations and future perspectives of SC-related therapy for IBD.

show abstract

“…Продемонстрированы возможность, безопасность и эффективность применения костномозговых МСК банка МРНЦ при язвенном колите и болезни Крона [13]. Установлено, что комбинированная клеточная и антицитокиновая терапия болезни Крона с перианальными поражениями достоверно способствует более частому и длительному закрытию простых свищей по сравнению с антибиотиками/иммуносупрессорами [14,15]. Кроме того показано, что трансплантация МСК способствует поддержанию более длительной клинической ремиссии у больных с люминальной формой болезни Крона по сравнению с группой больных, страдающих язвенным колитом [16,17] ных клеток на эффективность репарации кроветворения при использовании сублетальных доз циклофосфана [18].…”

unclassified

Cell biobank as a necessary infrastructure for the development and implementation of mesenchymal stem cell-based therapy in the treatment of anthracycline-induced cardiotoxicity. Literature review and own data

Гривцова

Popovkina

Dukhova

et al. 2020

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Cardiovascular diseases, along with cancer, are the leading causes of death worldwide. Although modern pharmacological treatment of various cardiomyopathies can slow the development of myocardial dysfunction, they have limited effectiveness in patients with end-stage disease. Many researchers believe that heart transplantation is the only radical treatment in this case. However, the lack of donors and the high operation cost require careful selection of surgical candidates. With the introduction of molecular and cell biology into medical practice, today, stem cell therapy can become an alternative method of nonsurgical restoration of myocardial functions. The most studied and attractive is the use of mesenchymal stem cells (MSCs). MSCs differ from hematopoietic stem cells used as support for hematopoiesis in high-dose chemotherapy by the following features: pronounced trophic effect, immune tolerance, the ability to suppress alloreactivity and autoimmune disorders. An important stage in the implementation of cell therapy is the creation of a cell biobank of MSCs. In A.F.Tsyb Medical Radiological Research Center, this work has been carried out since1984. Asignificant number of experimental studies have been carried out, confirming the possibility of clinical implementation of this approach. A method for obtaining stable cultures of MSCs and cardiomyoblasts from bone marrow cells was developed and approvals were obtained. Experimental studies of cell therapy are also being conducted to overcome anthracycline-induced cardiotoxicity in cancer patients.This article is devoted to practical application of MSC-based therapy, in particular, in cancer patients with cardiotoxicity, as well as to the issues of creating a cell biobank for treatment with MSCs.

show abstract

Stem Cell Therapy for Perianal Crohn’s Disease

Cited by 14 publications

References 1 publication

Mesenchymal stem cells transplantation for perianal fistulas: a systematic review and meta-analysis of clinical trials

Mesenchymal stem cells transplantation for perianal fistulas: a systematic review and meta-analysis of clinical trials

Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges

Cell biobank as a necessary infrastructure for the development and implementation of mesenchymal stem cell-based therapy in the treatment of anthracycline-induced cardiotoxicity. Literature review and own data

Contact Info

Product

Resources

About